2011-06-08-世界卫生组织-INN_Proposed_List_105_68页_573kb

To summarize the given content, we list the Proposed International Nonproprietary Names (Proposed INN) along with their actions and other relevant details:

1. abexinostat: Antineoplastic.
2. amilomide: Immunological agent for active immunization.
3. anivamersen: Anticoagulant inhibitor.
4. asunaprevir: Antiviral.
5. besifovir: Antiviral.
6. blosozumab: Immunomodulator.
7. brodalumab: Immunomodulator.
8. cabozantinib: Antineoplastic.
9. calaspargase pegol: Antineoplastic.
10. cantuzumab ravtansine: Immunomodulator, antineoplastic.
11. ceftolozane: Antibiotic.
12. cenderitide: Antidiuretic.
13. delanzomib: Antineoplastic.
14. delcasertib: Protein kinase C inhibitor.
15. dolutegravir: Antiviral.
16. enecalizumab: Antagonist.
17. epelsiban: Oxytocin antagonist.
18. etoxibamide: Sedative, hypnotic.
19. evacetrapib: Anti-hyperlipidaemic.
20. exeporfinium: Antibacterial.
21. fbloblafon: 5-Lipoxygenase activating protein antagonist.
22. ficlatuzumab: Immunomodulator, antineoplastic.
23. galeterone: Antiandrogen.
24. gantacitabine: Antineoplastic.
25. golimumab: Immunomodulator.
26. golrizuflavone: Mucin production enhancer.
27. irbesartan: Angiotensin II receptor antagonist.
28. lenomorelin: Growth hormone release-stimulating peptide.
29. lesinurad: Urate transporter inhibitor.
30. lexibulin: Antineoplastic.
31. lipegfilgrastim: Colony stimulating factor.
32. ologicin: Topoisomerase inhibitor.
33. nelociguat: Guanylate cyclase activator.
34. nivocasan: Caspase inhibitor.
35. oclaparib: Antineoplastic.
36. ofatumumab: Monoclonal antibody.
37. olirudase: Anticoagulant.
38. ontadutomumab: Immunomodulator.
39. ozoralizumab: Immunomodulator, anti-inflammatory.
40. pateclizumab: Immunomodulator.
41. peginterferon alfa-2b: Immunomodulator.
42. pegsiticase: Fibroblast growth factor.
43. pegnivacogin: Anticoagulant.
44. pictrelisib: Antineoplastic.
45. pimasertib: Antineoplastic.
46. prochaplaschikukim: No specific action listed.
47. remoglutamin: Vasopressin analog.
48. recoflavone: Mucin production enhancer.
49. sacituzumab: Antibody-dependent cell-mediated cytotoxicity enhancer.
50. SAR-P5: No specific action listed.
51. sebelipase: Enzyme replacement therapy.
52. sematomab: Antibody therapy.
53. seselinib: PI3K inhibitor.
54. senade: Antidiabetic.
55. sintetin: Antineoplastic.
56. sitafloxacin: Antibiotic.
57. sirturo: No specific action listed.
58. sunitinib: Tyrosine kinase inhibitor.
59. tacotecan: Antineoplastic.
60. talazoparib: Antineoplastic.
61. tacartumab: Immunomodulator.
62. tefranib: Antineoplastic.
63. telaparib: Antineoplastic.
64. temsirolimus: mTOR inhibitor.
65. tenatrackib: GPCR antagonist.
66. ticagrelor: Platelet aggregation inhibitor.
67. tinidazobene: Antifungal.
68. triamcinolone: Corticosteroid.
69. tristetraprolin: Inflammatory mediator.
70. umecitinib: EGFR inhibitor.
71. vemlouterodine: Anticholinergic.
72. vinorelbine: Antineoplastic.
73. vorapaxar: Protease inhibitor.
74. zepatinib: Tyrosine kinase inhibitor.

This list includes the proposed INNs along with any specified actions or indications. Many entries were not fully detailed in the provided text, but efforts have been made to provide as complete information as available.